A team of researchers from the University of Cambridge and Warwick Clinical Trials have revealed that Roche’s Herceptin is just as effective after a reduced treatment period of six months compared with the standard 12 months, in women with HER2 positive early-stage breast cancer.
This is a significant finding for a few reasons: the main one being that patients could receive less courses of treatment, which was found to be associated with reduced levels of side-effects.
Original Article: Study finds Herceptin use can be halved